These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. McNaught KS; Olanow CW Neurobiol Aging; 2006 Apr; 27(4):530-45. PubMed ID: 16207501 [TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Mandel S; Grunblatt E; Riederer P; Amariglio N; Jacob-Hirsch J; Rechavi G; Youdim MB Ann N Y Acad Sci; 2005 Aug; 1053():356-75. PubMed ID: 16179542 [TBL] [Abstract][Full Text] [Related]
4. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Ross CA; Pickart CM Trends Cell Biol; 2004 Dec; 14(12):703-11. PubMed ID: 15564047 [TBL] [Abstract][Full Text] [Related]
5. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease. Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126 [TBL] [Abstract][Full Text] [Related]
6. Does smoking reduce the risk of Parkinson's disease through stimulation of the ubiquitin-proteasome system? Chapman MA Med Hypotheses; 2009 Dec; 73(6):887-91. PubMed ID: 19540050 [TBL] [Abstract][Full Text] [Related]
7. The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1. Hol EM; van Leeuwen FW; Fischer DF Trends Mol Med; 2005 Nov; 11(11):488-95. PubMed ID: 16213790 [TBL] [Abstract][Full Text] [Related]
8. Does impairment of the ubiquitin-proteasome system or the autophagy-lysosome pathway predispose individuals to neurodegenerative disorders such as Parkinson's disease? Matsuda N; Tanaka K J Alzheimers Dis; 2010; 19(1):1-9. PubMed ID: 20061621 [TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-proteasome system dysfunction in Parkinson's disease: current evidence and controversies. Lim KL Expert Rev Proteomics; 2007 Dec; 4(6):769-81. PubMed ID: 18067415 [TBL] [Abstract][Full Text] [Related]
11. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575 [TBL] [Abstract][Full Text] [Related]
12. Does neurotrophic factor benefit to PD therapy via co-function with ubiquitin-proteasome system? Niu C; Zhang J; Mei J; Fu X Med Hypotheses; 2011 Apr; 76(4):589-92. PubMed ID: 21288653 [TBL] [Abstract][Full Text] [Related]
13. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Gallardo G; Schlüter OM; Südhof TC Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066 [TBL] [Abstract][Full Text] [Related]
14. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. McNaught KS; Olanow CW Ann Neurol; 2003; 53 Suppl 3():S73-84; discussion S84-6. PubMed ID: 12666100 [TBL] [Abstract][Full Text] [Related]
16. Role of iron in UPS impairment model of Parkinson's disease. Le W Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S158-61. PubMed ID: 24262171 [TBL] [Abstract][Full Text] [Related]
17. Ubiquitin-proteasome system and Parkinson's diseases. Betarbet R; Sherer TB; Greenamyre JT Exp Neurol; 2005 Feb; 191 Suppl 1():S17-27. PubMed ID: 15629758 [TBL] [Abstract][Full Text] [Related]